The chikungunya virus virus-like particle vaccine is well tolerated and shows high immunogenicity in both previous recipients ...

The chikungunya vaccination is recommended for those traveling to areas where there is a chikungunya outbreak.

Vaccine research has increasingly focused on virus-like particles (VLPs) due to their unique ability to mimic the structures of viruses without containing ...

In the Virus-Like Particle Translational Oncology Laboratory, Qizhi Cathy Yao, M.D., Ph.D. is developing non-infectious HIV virus-like particles (VLPs) as candidate HIV mucosal vaccines for both ...

The formation of VLP is depicted in Figure 1. Figure 1. The formation of a virus-like particle (VLP). Image Credit: Sino Biological Inc. To enable targeted drug research, Sino Biological has ...

Researchers have taken a major step towards producing a more affordable and lower-risk polio vaccine using virus-like particles (VLPs). These particles mimic the outer protein shell of poliovirus, but ...

The European Commission (EC) has authorised the marketing of Bavarian Nordic's Vimkunya - the first chikungunya vaccine approved in Europe for individuals as young as 12 years old. Vimkunya is a virus ...

that compared the safety and immunogenicity of a single intramuscular dose of Vimkunya (n=2559), a virus-like particle chikungunya vaccine, with placebo (n=424) in healthy participants 12 to 64 ...

Our virus-like particle vaccine platform enables us to provide highly targeted vaccines because we combine years of investment in vaccine research with advanced genetic engineering. This ...

The following is a summary of "Impact of HBsAg reduction via siRNA treatment on natural and vaccine (BRII-179)-induced ...

ProBioGen has expanded its protein and viral vector manufacturing capabilities at its Berlin headquarters, reinforcing its ...